Back

Cost-effectiveness of the next generation of RSV intervention strategies

2019-10-22 public and global health Title + abstract only
View on medRxiv
Show abstract

BackgroundWith a suite of promising new RSV prophylactics on the horizon, including long-acting monoclonal antibodies and new vaccines, it is likely that one or more of these will replace the current monoclonal Palivizumab programme. However, choosing the optimal intervention programme will require balancing the costs of the programmes with the health benefits accrued. MethodsTo compare the next generation of RSV prophylactics, we integrated a novel transmission model with an economic analysis....

Predicted journal destinations